Extended duration of active surveillance of small renal masses

A recent study published in the Journal of Urology evaluated the outcomes of 103 patients with small renal masses (<6 cm) who were on active surveillance. The patients were followed for a median of 55.5 months, and in that time only 1% died of metastatic renal cell carcinoma (RCC). Of the 103 patients, 51.5% survived without metastatic RCC and 45.6% died of other causes. Approximately 16% ultimately received treatment for metastatic disease.

The researchers concluded that active surveillance of small renal masses is a safe option, even after 5 years of follow-up. However, the data presented in this study are limited by the lack of strict active surveillance criteria and biopsy data. The authors recommend a comparative analysis of surveillance patients versus surgical patients to confirm that surveillance is appropriate in properly selected patients.

Read more in Journal of Urology here

Share this Post!


Related post

  TOP